Syndax Pharmaceuticals Inc (NAS:SNDX)
$ 20.28 0.17 (0.85%) Market Cap: 1.72 Bil Enterprise Value: 1.28 Bil PE Ratio: 0 PB Ratio: 3.50 GF Score: 53/100

Q2 2020 Syndax Pharmaceuticals Inc Earnings Call Transcript

Aug 06, 2020 / 08:30PM GMT
Release Date Price: $15 (+0.81%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Syndax Second Quarter 2020 Financial Results Conference Call. (Operator Instructions) I would now like to turn the conference over to your host, Ms. Melissa Forst. Please go ahead.

Melissa Forst
Argot Partners, LLC - SVP

Thank you, Grace. Welcome, and thank you to those of you joining us on the line and the webcast this afternoon for a review of Syndax' second quarter 2020 financial and operating results. I'm Melissa Forst of Argot Partners, and with me this afternoon to discuss the results and provide an update on the company's progress are Dr. Briggs Morrison, Chief Executive Officer; and Daphne Karydas, Chief Financial Officer. Also joining us on the call today for the question-and-answer session is Michael Metzger, President and COO; Dr. Michael Meyers, Chief Medical Officer; and Dr. Peter Ordentlich, Chief Scientific Officer. This call is being accompanied by a slide deck that has been posted to the company's website, so I would ask you to please turn to the forward-looking statements on

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot